Effects of a new TRH analogue,YM-14673 on the central nervous system

Summary The effects of a new TRH analogue, YM-14673 (N-[{(S)-4-oxo-2-azetidinyl}carbonyl]-L-histidyl-L-prolinamide dihydrate) on the central nervous system were compared with those of TRH. YM-14673 was 10–40 times more potent than TRH in antagonizing pentobarbital-induced sleep and hypothermia, and ethanol-induced hypothermia in mice. YM-14673 accelerated recovery from disturbed consciousness induced by concussive head trauma in mice and normalized the behavior and spontaneous EEG disturbed by electrolytic lesion of the hypothalamus in cats with 25 -100 times greater potency than that of TRH. In the tests on pentobarbital sleeping time and EEG disturbance, the cerebral activating activity of YM-14673 was 8 –36 times longer-lasting than that of TRH. These results indicate that YM-14673 possesses potent arousal effects on the central nervous system. The mode of action of YM-14673 was also discussed. Send offprint requests to M. Yamamoto     

Antagonizing effects of YM-14673, a new TRH derivative,on behavioral and electroencephalographic changes in reserpinized animals

Effects of YM-14673 (N-[{(S)-4-oxo-2-azetidinyl}-carbonyl]-l-histidyl-l-prolinamide dihydrate), a new TRH derivative, on reserpine-induced behavioural and electroencephalographic changes were observed in comparison with those of TRH. YM-14673 antagonized reserpine-induced hypothermia and decrease in convulsion threshold in mice. The number of PGO waves recorded from the lateral geniculate body was decreased by administration of YM-14673 in reserpinized cats. The anti-reserpine activity of intravenous YM-14673 was about 8–20 times more potent than that of TRH. In inhibiting reserpine-induced hypothermia, the oral ED_2°C relative to IV ED_2°C as an indirect indication of absorption rate of the drugs was 15 for both YM-14673 and TRH. These results suggest that YM-14673 possesses more potent facilitatory effects on the central monoamine systems than TRH.     

Effects of a new TRH analogue, YM-14673, on disturbance of passive avoidance learning in senescence-accelerated mice

Effects of a new TRH analogue, YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), on disturbance of passive avoidance behavior were observed in senescence-accelerated mice (SAM). Latency of step-through in SAM-P/8/Ta (SAM-P/8, senescence-prone substrain) was significantly shorter than that in SAM-R/1/Ta (SAM-R/1, senescence-resistant substrain). Successive oral administration of YM-14673 (1 and 10 mg/kg) and TRH (10 mg/kg) for 3 weeks prolonged the shortened latency of step-through. These results suggest that YM-14673 is more potent than TRH in antiamnesic activities.     

促甲状腺素释放激素类似物YM14673对小鼠学习记忆的影响

采用小鼠跳台法评价促甲状腺素释放激素类似物YM14673(ip 1 mg·kg^-1) 对正常成年小鼠被动回避学习记忆成绩的影响. 结果表明YM14673对东莨菪碱， 氯霉素和乙醇造成的小鼠记忆获得,巩固及再现障碍均有明显的改善作用.     

Pharmacological actions of a new TRH analogue, YM-14673, in rats subjected to cerebral ischemia and anoxia

The cerebral protective actions of a new thyrotropin releasing hormone (TRH) analogue, YM-14673, [Na-[[(S)-4-oxo-2-azetidinyl-carbonyl]-L-histidyl-L-prolinamide] dihydrate), were compared with those of CDP-choline (cerebral metabolic enhancer) and naloxone in rats rats subjected to unilateral carotid artery ligation and anoxic exposure (Levine rats). Drugs were administered intraperitoneally or orally 20, 80, and 140 min after anoxia. YM-14673 (0.03 to 1 mg/kg i.p. and 0.3 to 10 mg/kg p.o.) decreased the incidence of neurological deficits, such as hemiplegia and convulsion followed by coma and death, for 48 h after ischemia and anoxia. Both the increase in the brain water content and the degeneration of neurons in the cerebral cortex and thalamus were prevented by YM-14673 at a dose of 0.1 mg/kg (i.p.). CDP-choline (400 mg/kg i.p.), which is currently used in the therapy of cerebral vascular diseases, and naloxone (3 mg/kg i.p.) also decreased the incidence of the neurological deficits. These results suggest that YM-14673 protects Levine rats against neurological deficits, presumably by attenuating the development of brain edema and preventing neuronal damage. This compound may be useful in the therapeutic treatment of cerebral vascular diseases.     

Anticonvulsive properties of YM-14673, a new TRH analogue, in amygdaloid-kindled rats

Effects of YM-14673 (N alpha-[( (S)-4-oxo-2-azetidinyl]-carbonyl]-L- prolinamide dihydrate), a new TRH analogue, on the development of kindling and the duration of afterdischarge (AD) were observed in amygdaloid-kindled rats in comparison with those of TRH. The right medial amygdaloid nucleus was electrically stimulated once a day for establishment of kindling. YM-14673 and TRH were administered intraperitoneally 15 and 30 min prior to electrical stimulation from 2 days after the first stimulation, respectively, and the number of stimulations required for the development of generalized seizures was measured. YM-14673 (1 mg/kg) showed tendency to suppress the development of kindling (p less than 0.1), but TRH even at high dose (10 mg/kg) showed little effect on it. In addition, the experiment for the AD duration was conducted in full-kindled rats from one day after at least 3 reproducible generalized seizures were elicited by electrical stimulation of the medial amygdaloid nucleus once a day. Both YM-14673 (1 mg/kg) and TRH (10 mg/kg) administered 15 and 30 min prior to electrical stimulation of the amygdala, respectively, significantly shortened the AD duration in full-kindled rats. At these doses, both drugs desynchronized spontaneous cortical electroencephalogram (EEG) in normal rats. These results indicate that YM-14673 seems to possess anticonvulsive property in rats.     

Effects of thyrotropin-releasing hormone on behavioral disturbances in middle cerebral artery-occluded rats

The effects of thyrotropin releasing hormone (TRH) on behavioral and histological changes were studied in rats subjected to left middle cerebral artery occlusion. The drug was given i.p. once or several times a day from 1 week after occlusion for 2 weeks. A single administration of TRH (1 and 10 mg/kg) did not affect the neurological deficits, but recovery of the deficits was accelerated by multiple administration (7 times a day) of TRH and single administration (once a day) of YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), a new TRH analogue with a longer half-life. Both YM-14673 and single (1 and 10 mg/kg) and multiple administration of TRH ameliorated the disturbance of passive avoidance learning. Neuronal degeneration in the cerebral cortex and striatum was not influenced by the administration of TRH. Thus, we found that neurological deficits and disturbance of passive avoidance learning behavior in middle cerebral artery-occluded rats could be ameliorated by administration of TRH.     

Central dopaminergic actions of YM-14673, a new TRH analogue, in rodents

The effects of a new TRH analogue, YM-14673 (N-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate) on spontaneous movement, sniffing, climbing, licking, biting and circling behaviors were compared with those of TRH and methamphetamine, in rodents. YM-14673 in a dose of 1 mg/kg (i.p.) enhanced spontaneous motor activity in rats, and induced sniffing and climbing behaviors in mice. The licking and biting behaviors were not induced by administration of YM-14673 even in a high dose (30–100 mg/kg i.p.) to mice. In addition, ipsilateral circling did not follow the i.p. administration of YM-14673 in rats receiving cis-flupenthixol unilaterally into the striatum. YM-14673 was about 20–30 times more potent than TRH to induce sniffing and climbing behaviors and to increase spontaneous movement. The sniffing and climbing behaviors induced by administration of YM-14673 and TRH were antagonized by treatment with haloperidol and -methyl-para-tyrosine (-MT). Methamphetamine (0.5–10 mg/kg i.p.), unlike YM-14673, showed significant pharmacological effects in all behavioral experiments, so that the pharmacological profile of YM-14673 was different from that of methamphetamine. These results suggest that both YM-14673 and TRH induced behavioral changes, presumably due to facilitatory effects on the central dopaminergic system.     

Effects of YM-14673, a new thyroid-releasing hormone analogue, on neurological deficits in stroke-prone spontaneously hypertensive rats

The effects of YM-14673, a new thyroid-releasing hormone (TRH) analogue (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), on neurological deficits were examined in stroke-prone spontaneously hypertensive rats (SHRSP). The neurological deficits were evaluated for more than 21 days after stroke. Administration of YM-14673 was started the day stroke was observed and repeated daily for 3 weeks. YM-14673 (0.1 and 0.3 mg/kg i.p.) improved the neurological deficits and reduced mortality. These results demonstrate that YM-14673 mitigates cerebral ischemic changes in SHRSP.     

Effects of a new analogue of thyrotropin-releasing hormone on pentobarbital-induced sleeping time in rodents

The effects of a new analogue of TRH, YM-14673 (N-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate) on pentobarbital-sleeping time were observed in comparison with those of TRH in rodents. The YM-14673 was administered intravenously, orally and intramuscularly. In all cases it reduced pentobarbital-sleeping time in rats and/or mice in a dose-dependent manner. The analeptic activity of YM-14673 was about 10 times greater than that of TRH. Analeptic action was also observed with successive intravenous injections of YM-14673, once daily for 5 and 14 days in mice, suggesting that the drug induced no tolerance. In addition, there was evidence that the pituitary-thyroid axis was not necessary for the analeptic effects of YM-14673. In particular, it was noted that hypophysectomy did not reduce the antagonism by YM-14673 of pentobarbital-induced sleep and intracerebrally administered YM-14673 produced analeptic actions in mice. Pretreatment with atropine and baclofen antagonized the ability of YM-14673 to reduce sleep, induced by pentobarbital in mice. However, the analeptic action of YM-14673 was not reduced by the administration of haloperidol and phentolamine. These results suggest that YM-14673 produced facilitatory effects on the central nervous system, independent of an effect on the pituitary gland, and that the antagonizing effects by YM-14673 on the actions of pentobarbital may be affected by activation of the central cholinergic system as well as by inhibition of the GABA-ergic system.     

Effects of a new analog of thyrotropin-releasing hormone, N alpha-[(S)-4-oxo-2-azetidinyl) carbonyl]-L-histidyl-L-prolinamide dehydrate (YM-14673) on spinal reflex potentials and flexor reflexes in spinalized rats

Experiments were performed on spinalized rats, transected at the Cl level. The intravenous administration of TRH and its analog YM-14673 (N alpha-[(S)-4-oxo-2-azetidinyl) carbonyl]-L-histidyl-L-prolinamide dehydrate) produced marked increases in the amplitude of mono- and polysynaptic reflex potentials and those of the withdrawal flexor reflexes. The effects of YM-14673 were stronger and longer-lasting than those of TRH. The stimulant action of TRH and YM-14673 on the flexor reflexes was not antagonized by prazosin, chlorpromazine, haloperidol or cyproheptadine, suggesting no involvement of the release of catecholamines or serotonin in the stimulant effects of TRH and its analog. Therefore, YM-14673 may be beneficial for the treatment of several spinal motor neuron diseases.     

Effect of YM-14673, a new thyrotropin releasing hormone analogue, on ataxic gait in cytosine arabinoside-treated mice

The effect of YM-14673, a new thyrotropin releasing hormone (TRH) analogue, on ataxic gait in mice treated with cytosine arabinoside was observed and compared with the effect of TRH. Ataxic gait was observed after administration of cytosine arabinoside in a dose of 40 mg/kg (s.c.) on the second and third postnatal days. The falling index, the ratio of the number of inversions to spontaneous motor activity, is regarded as an index of ataxia. YM-14673 significantly reduced the falling index. YM-14673 was about 30 times more potent than TRH in reducing the ataxic activity. These results suggest that YM-14673 ameliorates the ataxic gait of cytosine arabinoside-treated mice.     

促甲状腺素释放激素(TRH)类似物YM14673对大鼠脑损伤并发脑水肿的作用

用雄性Wistar大鼠,采用Feeney等的落体撞击法造成左顶颅脑挫伤。动物随机分组,给于TRH类似物YM14673(0.1 mg·kg^-1或1.0 mg.kg^-1,ip)或等体积生理盐水。治疗组可明显地减轻脑水肿。     

促甲状腺素释放激素类似物YM14673对大鼠脑缺血再灌注致学习记忆功能障碍的作用

目的观察促甲状腺素释放激素类似物ＹＭ１４６７３对大鼠脑缺血再灌注损伤致学习记忆功能障碍的作用及其对脑脂质过氧化物的影响。方法用双侧颈总动脉反复短暂夹闭法造成大鼠脑缺血再灌注模型,通过跳台和Ｍｏｒｉｓ水迷津实验观察促甲状腺素释放激素类似物ＹＭ１４６７３对大鼠学习记忆功能障碍的作用,用ＴＢＡ法了解ＹＭ１４６７３对大鼠脑脂质过氧化作用的影响。结果ＹＭ１４６７３（１ｍｇ·ｋｇ－１,ｉｐ）明显地改善了脑缺血再灌注所致的大鼠学习记忆功能障碍。实验表明ＹＭ１４６７３（１ｍｇ·ｋｇ－１,ｉｐ）能抑制体内氧自由基的大量生成,但体外实验ＹＭ１４６７３（００１～１０μｍｏｌ·Ｌ－１）却没有表现出清除羟自由基的能力。结论ＹＭ１４６７３对大鼠脑缺血再灌注致学习记忆障碍有明显的改善作用,但这不是ＹＭ１４６７３直接清除氧自由基的结果     

Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity

A new benzamide, cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) exhibited more potent and longer-lasting inhibitory effects on apomorphine-induced behaviours (stereotyped behaviour, emesis and hypothermia), and methamphetamine-induced stereotyped behaviour, conditioned avoidance response and open field behaviour than either structurally similar benzamides (YM-0850 and sulpiride) or calssical neuroleptics [chlorpromazine(CPZ) and haloperidol(HPD)]. Such inhibitory effects of YM-09151-2 relative to cataleptogenicity were greater than those of CPZ and HPD. In contrast, sulpiride elicited few of the neuroleptic effects described above. YM-09151-2, a potent inhibitor for dopamine-sensitive adenylate cyclase (Ki: 3.0 nM) reduced, in a selective manner, the binding of [³H]dopamine to the dopamine D₁ receptor (Ki: 4.8 nM) associated with adenylate cyclase rather than to the dopamine D₂ receptor (Ki: 0.98 M) independent of adenylate cyclase. Sulpiride, on the contrary, inhibited only the binding to the dopamine D₂ receptor. CPZ and HPD antagonized [³H]dopamine non-selectively at the two distinct dopaminergic receptors. These results suggest that YM-09151-2 is a potent and long-lasting neuroleptic with a highly selective blocking action on the dopamine D₁ receptor.     

Morphine-like discriminative stimulus effects of opioid peptides: possible modulatory role ofd-Ala2-d-Leu5-enkephalin (DADL) and dynorphin A(1-13)

The role of the different opioid receptors was studied in rats trained to discriminate SC injections of 3.0 mg/kg morphine from saline by tests for generalization to graded doses of morphine and receptor-selective peptides administered into the lateral cerebral ventricle. Dose-dependent morphine-like stimulus effects were produced over a wide range of doses (0.001–30 g), depending upon ligand and animal, by morphine, by themu-selective peptides DAGO[d-Ala²-NMePhe⁴-Gly(ol)-enkephalin] and FK33824[d-Ala²,NMePhe⁴-Met(O)⁵-(ol)-enkephalin], and by thedelta-selective peptide, DADL[d-Ala²,d-Leu⁵enkephalin]. The order of relative potency of these substances was: FK33824>DAGO>morphine>DADL. In contrast, DPLPE[d-Pen²,l-Pen⁵)enkephalin], which has much greaterdelta receptor selectivity than does DADL, and dynorphin A(1-13) (0.1–10 g), akappa-receptor agonist, engendered choice responding appropriate for saline. When 1.0 g DADL, a dose lacking morphine-like discriminative effects, was administered concurrently with SC morphine, the stimulus effects of morphine were potentiated. Concurrent administration of 10 g dynorphin A(1-13) and morphine attenuated the stimulus effects of morphine inconsistently. These results support previous findings thatmu-opioid receptors are of primary importance in mediating the morphine-like discriminative effects of opioid peptides. They also suggest that morphine-like discriminative effects can be modulated by other types of opioid receptors.     

Antinociceptive activity of glycosidic enkephalin analogues

The antinociceptive activity of two new enkephalin analogues:N ^1.5-(-d-glucopyranosyl)[d-Met², Pro⁵]enkephalinamide andN ^1.5-(-d-galactopyranosyl)[d-Met², Pro⁵]enkephalinamide was assessed using the tail immersion and paw pressure behavioural tests. Both enkephalin analogues appear to be more active than morphine when injected either into the fourth ventricle or intrathecally; the galactose analogue is more than 5000 times more active than morphine when injected into the fourth ventricle. The analgesic effects produced by the analogues are partially reversed by SC naloxone (0.1 mg/kg) and totally reversed when the dose of naloxone used was 1 mg/kg, suggesting that the analogues act upon more than one type of opiate receptor (/).     

Cannabinols and feeding in sheep

Marijuana, long used for the euphoria which results, recently has been found to stimulate hunger in humans but in several laboratory animals cannabinoids decrease food intake. Sheep, relatively more sensitive to chemicals that affect food intake, were injected IV with the d-and l-isomers of tetrahydrocannabinol and with a 9-aza-cannabinol) 9-AC) (8-(1,2-dimethylheptyl)-5,5-dimethyl-5H-[1]benzopyranol[3,4]pyridin-10-01, HCl) and feeding behavior was monitored. In the first 30 min, food intake was increased by the l-isomer and by 9-AC but not affected by d- ⁹-THC. After 24h, feed intake was decreased by at least one dose of d-and l- ⁹-THC and 9-AC. The l- but not d-isomer was active at very low doses compared with doses used in many laboratory animals.     

Enhancement of δ- but not μ-opiate agonist binding by calcium

Summary Present evidence for distinction of 2 types of opiate receptor sites in rat brain homogenates originates from different relative affinities of morphine-like alkaloids and enkephalins to -or enkephalin and - or morphine-receptor sites. We now report that Ca²⁺ in a physiological dose range (0.5–3 mM) enhances the binding of ³H-enkephalin in hypotonically treated rat brain membranes, whereas specific binding of ³H-morphine-like alkaloids is not affected. Furthermore, the potency of [d-Ala², d-Leu⁵]-enkephalin to inhibit [³H]-diprenorphine and [³H]-ethylketazocine binding increased in the presence of Ca²⁺, whereas an increase in potency of [d-Ala², d-Leu⁵]-enkephalin to inhibit binding of -receptor ligands was not observed. Kinetic analysis revealed that Ca²⁺ decreased the rate of dissociation of [d-Ala², d-Leu⁵]-enkephalin without affecting the rate of association, thereby increasing the affinity. However, in saturation binding studies, performed in diencephalic membranes, in which [d-Ala², d-Leu⁵]-enkephalin binds predominantly to -receptors, Ca²⁺ also increased the binding affinity of [³H]-[d-Ala², d-Leu⁵]-enkephalin. Double reciprocal analysis suggested a mixed competitive-noncompetitive type of inhibition of [d-Ala², d-Leu⁵]-enkephalin binding by dihydromorphine. Thus, the interactions of - and -opiate ligands with -receptors may involve topographically different, but closely related binding sites, located on a single receptor molecule.Abbreviations DADL [d-Ala², d-Leu⁵]-enkephalin - DHM dihydromorphine - met-enkephalin methionine-enkephalin - leu-enkephalin leucine-enkephaline - FK 33-824 [d-Ala², MePhe⁴, Met(O)-ol]-enkephalin - EGTA ethyleneglycol-bis-(-aminoethylether) N, N'-tetraacetic acid - TRIS Tris (hydroxymethyl)-aminomethan     

Effect of LP-805, a releaser of endothelium-derived nitric oxide,on systemic vasodilatation in vivo

Summary We have investigated relations between hypotensive responses to LP-805, a newly synthesized vasodilator, and the production of nitric oxide (NO), in anesthetized rats. LP-805 (0.1–0.5 mg/kg, i.v.) or acetylcholine (ACh) (0.3 – 3.0 g/kg, i.v.) caused a dose-dependent transient decrease in diastolic blood pressure. The decrease induced by 0.3 mg/kg LP-805 (i.v.) was partially inhibited by pretreatment with N^G-nitro-l-arginine (LNNA), a specific inhibitor of endothelial NO synthase, but the responses to lower or higher doses of LP-805 (0.1 or 0.5 mg/kg, i.v.) were not affected. The dose-dependent decrease in diastolic blood pressure, caused by LP-805, was not affected by pretreatment with l- or d-arginine. The dose-dependent decrease in diastolic blood pressure caused by ACh was not affected by pretreatment with L-NNA or with l- or d-arginine. The hypotensive response to 20-min infusions of LP-805 (100 g/kg per min) wassignificantly inhibited by pretreatment with L-NNA (10 mg/kg, i.v.). The half-recovery times (T_1/2) of LP-805 or ACh-induced depressor responses were shortened by pretreatment with L-NNA. They were prolonged by l-arginine, but not by d-arginine. This shortening, by L-NNA, of the half-recovery time after LP-805 or ACh was reversed by l-arginine, but not by d-arginine. The T_/2 of the LP-805-induced hypotensive response was not affected by pretreatment with indomethacin (1 mg/kg, i.v.). In the presence of L-NNA (10 mg/kg, i.v.), the T_/2 of the LP-805-induced hypotensive response was not affected by pretreatment with indomethacin. The results suggest that the LP-805-induced hypotensive response may be related to direct or indirect activation of NO synthase in vascular endothelial cells, and to release of endothelium-derived NO. Correspondence to M. Inazu at the above address